New era of individualized pharmacotherapy

Abstract

Abstract: Along with deep scientific research and continual development of pharmacogenetics and pharmacogenomics, the new era of individual pharmacotherapy will come true in the future. The genetic variations of drug related proteins including drug metabolism enzymes, drug transport proteins, and drug active receptors and or targets are basic factors resulting in individual and ethnic differences in drug response. Choosing the suitable drugs and dosages according to genotypes of drug related proteins in patients will furthest improve the pharmacotherapy efficacy and reduce the adverse drug reaction and toxic effect of drugs.

Key words: pharmacogenetics, individual difference, genetic polymorphism, drug responsiveness

CLC Number:

R968

LIU Zhao-qian, ZHOU Hong-hao. New era of individualized pharmacotherapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(1): 1-6.

References

[1] Zhou HH, Liu ZQ. Ethnic differences in drug metabolism[J]. Clin Chem Lab Med, 2000;38: 899-903.
[2] Zhou HH, Wood AJJ. Stereoselective disposition of carvedilol is determined by CYP2D6[J]. Clin Pharmacol Ther, 1995;57: 518-524.
[3] De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin in human[J]. J Bio Chem, 1994;269: 15419-15422.
[4] De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect for the polymorphism of S-mephenytoin in Japan[J]. Mol Pharmacol, 1994;46: 594-598.
[5] He N, Yan FX, Huang SL, et al. CYP2C19 genotype and Smephenytoin4(-hydroxylation phenotype in Chinese Dai population[J]. Eur J Clin Pharmacol, 2002;58: 15-18.
[6] 肖洲生, 谢红光, 何楠, 等. 基因剂量对S-美芬妥因羟化酶活性的影响[J]. 中华医学杂志, 1996;76: 389-390.
[7] Qin XP, Xie HG, Wang W, et al. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects[J]. Clin Pharmacol Ther, 1999;66: 642-646.
[8] Xu ZH, Wang W, Zhao XJ, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes[J]. Br J Clin Pharmacol, 1999;48: 416-423.
[9] Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin[J]. Pharmacogenetics, 2001;11341-11348.
[10] Wang JH, Liu ZQ, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19[J]. Clin Pharmacol Ther, 2001;70: 42-47.
[11] Liu ZQ, Zhu B, Tan YF, et al. O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes[J]. J Pharmacol Exp Ther, 2002;300: 105-111.
[12] Yu BN, Chen GL, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19[J]. Drug Metab Dispos, 2003;31: 1255-1259.
[13] Ito S, Ieiri I, Tanabe M, et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2 cMOAT in healthy Japanese subjects[J]. Pharmacogenetics, 2001;11: 175-184.
[14] Min DI, Lee M, KU YM, et al. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers[J]. Clin Pharmacol Ther, 2000;68: 478-486.
[15] Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphism of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo[J]. Proc Natl Acd Sci USA, 2000;97: 3473-3478.
[16] Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects[J]. Pharm Res, 2001;18: 1400-1404.
[17] Liu ZQ, Liu J, Xiang ZH, et al. Distributive characteristics of Ser49Gly and Gly389Arg genetic polymorphisms of β1-adrenoceptor in Chinese Han and Dai populations[J]. Acta Pharmacol Sin, 2006;27: 254-258.
[18] Liu J, Liu ZQ, Tan ZR, et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol[J]. Clin Pharmacol Ther, 2003;74: 372-379.
[19] Liu J, Liu ZQ, Yu BN, et al. ( 1-Adrenergic receptor haplotype influences the response to metoprolol monotherapy in patients with essential hypertension[J]. Clin Pharmacol Ther, 2006;80: 23-32.
[20] 莫玮, 刘洁, 周宏灏, 等. 高血压人群中β2 肾上腺素受体遗传多态性与肥胖相关性研究[J]. 中国药理学通报, 2006;22: 154-159.
[21] 刘昭前, 莫玮, 俞群军, 等. β3 肾上腺素受体遗传多态性与肥胖和高血压的相关性研究[J]. 中国现代医学杂志, 2006;16: 1811-1814.